Corlieve’s Leadership Team, Board Members and Advisors provide expertise and a passion for pursuing novel scientific approaches in neuroscience, epilepsy, gene therapy, and building sustainable companies.
Corlieve’s Leadership Team, Board Members and Advisors provide expertise and a passion for pursuing novel scientific approaches in neuroscience, epilepsy, gene therapy, and building sustainable companies.
Epilepsy is a neurological disorder that can affect people of all ages. It can cause several health issues, most notably unpredictable seizures. Epilepsy is considered a spectrum condition with a broad range of seizure types.
Temporal lobe epilepsy (TLE) is the most common form of drug resistant adult epilepsy, representing approximately 60% of all cases. It is characterised by recurrent, unprovoked seizures that originate in the temporal lobe of the brain. TLE is focal in nature, meaning it originates in a specific brain region, and the hippocampus is one of the major focus areas for chronic seizures in TLE.
TLE is associated with high morbidity and increased mortality. There are profound impacts for people affected, including memory disorders, an increased incidence of depression, and personality and behavioural changes.
Investors
Kurma Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions.
Idinvest Partners is a leading European mid-market private equity firm. With €8bn under management, the firm has developed several areas of expertise including innovative start-up venture capital transactions; mid-market private debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services.
Idinvest Partners is a leading European mid-market private equity firm. With €8bn under management, the firm has developed several areas of expertise including innovative start-up venture capital transactions; mid-market private debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services.